Literature DB >> 16298964

Fluorescently tagged canine adenovirus via modification with protein IX-enhanced green fluorescent protein.

Long P Le1, Jing Li1, Vladimir V Ternovoi1, Gene P Siegal2,1, David T Curiel1.   

Abstract

Canine adenovirus type 2 (CAV2) has become an attractive vector for gene therapy because of its non-pathogenicity and the lack of pre-existing neutralizing antibodies against this virus in the human population. Additionally, this vector has been proposed as a conditionally replicative adenovirus agent under the control of an osteocalcin promoter for evaluation in a syngeneic, immunocompetent canine model with spontaneous osteosarcoma. In this study, a CAV2 vector labelled with the fluorescent capsid fusion protein IX-enhanced green fluorescent protein (pIX-EGFP) was developed. Expression of the fluorescent fusion-protein label in infected cells with proper nuclear localization, and incorporation into virions, could be detected. The labelled virions could be visualized by fluorescence microscopy; this was applicable to the tracking of CAV2 infection, as well as localizing the distribution of the vector in tissues. Expression of pIX-EGFP could be exploited to detect the replication and spread of CAV2. These results indicate that pIX can serve as a platform for incorporation of heterologous proteins in the context of a canine adenovirus xenotype. It is believed that capsid-labelled CAV2 has utility for vector-development studies and for monitoring CAV2-based oncolytic adenovirus replication.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16298964     DOI: 10.1099/vir.0.80968-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  12 in total

1.  Fusion of Large Polypeptides to Human Adenovirus Type 5 Capsid Protein IX Can Compromise Virion Stability and DNA Packaging Capacity.

Authors:  Kathy L Poulin; Emily R McFall; Grace Chan; Natacha B Provost; Carin Christou; Adam C Smith; Robin J Parks
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

2.  Three-dimensional structure of canine adenovirus serotype 2 capsid.

Authors:  Guy Schoehn; Majida El Bakkouri; Céline M S Fabry; Oliver Billet; Leandro F Estrozi; Long Le; David T Curiel; Andrey V Kajava; Rob W H Ruigrok; Eric J Kremer
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

Review 3.  Evolving gene therapy approaches for osteosarcoma using viral vectors: review.

Authors:  M A Witlox; M L Lamfers; P I J M Wuisman; D T Curiel; G P Siegal
Journal:  Bone       Date:  2006-12-26       Impact factor: 4.398

4.  Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid.

Authors:  Julie L Boyer; Carolina Sofer-Podesta; John Ang; Neil R Hackett; Maria J Chiuchiolo; Svetlana Senina; David Perlin; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2010-07       Impact factor: 5.695

5.  In vitro dynamic visualization analysis of fluorescently labeled minor capsid protein IX and core protein V by simultaneous detection.

Authors:  Hideyo Ugai; Minghui Wang; Long P Le; David A Matthews; Masato Yamamoto; David T Curiel
Journal:  J Mol Biol       Date:  2009-10-21       Impact factor: 5.469

Review 6.  Armed replicating adenoviruses for cancer virotherapy.

Authors:  J J Cody; J T Douglas
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

7.  Tropism-modification strategies for targeted gene delivery using adenoviral vectors.

Authors:  Lynda Coughlan; Raul Alba; Alan L Parker; Angela C Bradshaw; Iain A McNeish; Stuart A Nicklin; Andrew H Baker
Journal:  Viruses       Date:  2010-10-13       Impact factor: 5.818

8.  Derivation of a triple mosaic adenovirus for cancer gene therapy.

Authors:  Yizhe Tang; Hongju Wu; Hideyo Ugai; Qiana L Matthews; David T Curiel
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

9.  The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution.

Authors:  Elena Seiradake; Daniel Henaff; Harald Wodrich; Olivier Billet; Matthieu Perreau; Claire Hippert; Franck Mennechet; Guy Schoehn; Hugues Lortat-Jacob; Hanna Dreja; Sandy Ibanes; Vasiliki Kalatzis; Jennifer P Wang; Robert W Finberg; Stephen Cusack; Eric J Kremer
Journal:  PLoS Pathog       Date:  2009-01-02       Impact factor: 6.823

10.  A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors.

Authors:  Anitra L Farrow; Binghao J Peng; Linlin Gu; Alexandre Krendelchtchikov; Qiana L Matthews
Journal:  Viruses       Date:  2016-03-10       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.